Current Treatment Options in Oncology

, Volume 8, Issue 3, pp 252–260

Induction Chemotherapy for Head and Neck Squamous Cell Carcinomas (SCCHN)

Head and Neck Cancer

Opinion statement

Induction chemotherapy for squamous cell carcinoma of the head and neck has long been known to be highly active with tumor responses observed in a high percentage of patients. More recent studies have added taxane to traditional platin and infusional fluorouracil regimens. Docetaxel, cisplatin and 5-fluorouracil (TPF) is presently studied in prospective controlled trials to better define the efficacy and potential toxicity of sequential treatment with TPF followed by concomitant chemoradiotherapy. We await the results of these trials before we accept induction chemotherapy as a standard treatment and to best identify the subgroups of patients who may be most likely to benefit from the approach.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Adelstein DJ: Induction chemotherapy in head and neck cancer. Hematol Oncol Clin North Am 1999, 13(4):689–698CrossRefPubMedGoogle Scholar
  2. 2.
    Cohen EE, Lingen MW, Vokes EE: The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004, 22(9):1743–1752CrossRefPubMedGoogle Scholar
  3. 3.
    Forastiere AA, Goepfert H, Maor M, et al.: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003, 349(22):2091–2098CrossRefPubMedGoogle Scholar
  4. 4.
    Merlano M, Vitale V, Rosso R, et al.: Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 1992, 327(16):1115–1121PubMedCrossRefGoogle Scholar
  5. 5.
    Calais G, Alfonsi M, Bardet E, et al.: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999, 91(24):2081–2086CrossRefPubMedGoogle Scholar
  6. 6.
    Jeremic B, Shibamoto Y, Milicic B, et al.: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000, 18(7):1458–1464PubMedGoogle Scholar
  7. 7.
    Brizel DM, Albers ME, Fisher SR, et al.: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998, 338(25):1798–1804CrossRefPubMedGoogle Scholar
  8. 8.
    Wendt TG, Grabenbauer GG, Rodel CM, et al.: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998, 16(4):1318–1324PubMedGoogle Scholar
  9. 9.
    Staar S, Rudat V, Stuetzer H, et al.: Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy–results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001, 50(5):1161–1171CrossRefPubMedGoogle Scholar
  10. 10.
    Adelstein DJ, Li Y, Adams GL, et al.: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003, 21(1):92–98CrossRefPubMedGoogle Scholar
  11. 11.
    Huguenin P, Beer KT, Allal A, et al.: Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004, 22(23):4665–4673. Epub 2004 Nov 8Google Scholar
  12. 12.
    Budach V, Stuschke M, Budach W, et al.: Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95–06 Prospective Randomized Trial. J Clin Oncol 2005, 23(6):1125–1135CrossRefPubMedGoogle Scholar
  13. 13.
    Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000, 355(9208):949–955PubMedGoogle Scholar
  14. 14.
    Ang KK: Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: Are we addressing burning subjects? J Clin Oncol 2004, 22(23):4605–4607CrossRefGoogle Scholar
  15. 15.
    Monnerat C. Faivre S, Temam S, et al: End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Annal Oncol 2002, 13:995–1006Google Scholar
  16. 16.
    Brockstein B, Haraf DJ, Rademaker AW, et al.: Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004, 15(8):1179–1186CrossRefPubMedGoogle Scholar
  17. 17.
    Adelstein DJ, Leblanc M: Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? J Clin Oncol 2006, 24(17):2624–2628CrossRefPubMedGoogle Scholar
  18. 18.
    Wolf GT et al. (The Department of Veterans Affairs Laryngeal Cancer Study Group): Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991, 324(24):1685–1690Google Scholar
  19. 19.
    Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T: Larynx preservation in pyriform sinus cancer: preliminary results of a European organization for research and treatment of cancer phase III trial. EORTC head and neck cancer cooperative group. J Natl Cancer Inst 1996, 88(13):890–899CrossRefPubMedGoogle Scholar
  20. 20.
    Calais G, Pointreau Y, Alfonsi M, et al.: Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000–01. Proc Am Soc Clin Onc 2006, 24(No18S):5506Google Scholar
  21. 21.
    Forastiere AA, Maor M, Weber RS, et al.: Long-term results of intergroup RTOG 91–11: A phase III trial to preerve the larynx-Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus therapy. Proc Am Soc Clin Onc 2006, 24(No18S):5517Google Scholar
  22. 22.
    Urba S, Wolf G, Eisbruch A, et al.: Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: A new treatment paradigm. J Clin Oncol 2006, 24:593–598CrossRefPubMedGoogle Scholar
  23. 23.
    Laccourreye O, Brasnu D, Bassot V, et al.: Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete responders: five-year results. J Clin Oncol 1996, 14(8):2331–2336PubMedGoogle Scholar
  24. 24.
    Kies MS, Sturgis E, Sabichi A, et al.: Induction chemotherapy followed by surgical resection for young patients with squamous cell carcinoma of the oral tongue (SCC/T). Proc Am Soc Clin Oncol 2005, 23(No 16S):5515Google Scholar
  25. 25.
    Paccagnella A, Orlando A, Marchiori C, et al.: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994, 86(4):265–272CrossRefPubMedGoogle Scholar
  26. 26.
    Domenge C, Hill C, Lefebvre JL, et al.: Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d’Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 2000, 83(12):1594–1598CrossRefPubMedGoogle Scholar
  27. 27.
    Posner MR: Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy. Oncologist 2005, 10(Suppl 3):11–19CrossRefPubMedGoogle Scholar
  28. 28.
    Posner MR, Colevas AD, Tishler RB: The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin Oncol 2000, 27(4 Suppl 8):13–24PubMedGoogle Scholar
  29. 29.
    Kies MS, Haraf DJ, Athanasiadis I, et al.: Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol 1998, 16(8):2715–2721PubMedGoogle Scholar
  30. 30.
    Haddad R, Tishler RB, Norris CM, et al.: TPF-based induction chemotherapy for head and neck cancer and the case for sequential, combined modality treatment. Oncologist 2003, 8:35–44Google Scholar
  31. 31.
    Haddad R, Wirth L, Posner M: The integration of chemotherapy in the curative treatment of locally advanced head and neck cancer. Expert Rev Anticancer Ther 2003, 3:331–338Google Scholar
  32. 32.
    Machtay M, Rosenthal DI, Hershock D, et al.: Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J Clin Oncol 2002, 20(19):3964–3971CrossRefPubMedGoogle Scholar
  33. 33.
    Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al.: Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005, 23(34):8636–8645CrossRefPubMedGoogle Scholar
  34. 34.
    Vermorken JB, Remenar E, van Herpen C, et al: Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck: A phase III trial of the EORTC head and neck cancer group (EPORTC #24971). J Clin Oncol 2004, 22:490s, (suppl. abstr 5508)Google Scholar
  35. 35.
    Posner M: Sequential combined modality therapy a phase III study: TAX 324 TPF vs PF followed by chemoradiotherapy. Special presentation. American Society of Clinical Oncology Meeting; Atlanta, Georgia, 2006Google Scholar

Copyright information

© Current Science Inc. 2007

Authors and Affiliations

  1. 1.Department of Thoracic/Head and Neck Medical OncologyUniversity of Texas, M. D. Anderson Cancer CenterHoustonUSA

Personalised recommendations